Email Updates
Press Release/Announcement
FDA recommends health care professionals discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder.
August 5, 2020
MedWatch Safety Alert. Silver Spring, MD: US Food and Drug Administration. July 23, 2020.
Accidental misuse of prescription opiates for pain can result in addiction, overdose and death. This announcement outlines new federal labeling requirements for opiates and treatments for opioid use disorder. The FDA calls for health care professionals to educate patients about naloxone when prescribing opioid medications to improve the safety of patients taking opiates.
